BCR-ABL Cellular Phosphorylation Assay Service

BCR-ABL Cellular Phosphorylation Assay (intracellular kinase activity assay) for compound screening and profiling in intact cells

Target Overview

Target Description

BCR-ABL is the result of a genetic translocation of the ABL1 gene to the BCR gene leading to the so called Philadelphia chromosome. The resulting fusion protein represents a constitutively active version of the cytoplasmic tyrosine kinase ABL1 which is associated with leukemic diseases such as acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML).

HGNC Reference



ABL, JTK7, p150, c-ABL, v-abl

Cell Line


Target Expression


Assay Properties

Assay Description

In the human CML cell line K562, ABL1 is constitutively active due to the BCR-ABL fusion. BCR-ABL activity is potently inhibited in the presence of cognate BCR-ABL inhibitors such as Dasatinib (BMS-354825) and Imatinib (STI571/Gleevec) (see Fig. 1). Phospho-BCR-ABL levels are quantified by Sandwich-ELISA technique.


Substrate phosphorylation as a readout of intracellular kinase activity via ELISA

Screening Location

Freiburg, Germany

Further Information

More information can be found on our website Cellular Phosphorylation Assay Services.

Reference compound IC50 for BCR-ABL

Reference compound IC50 for BCR-ABL

Dasatinib (BMS-354825) and Imatinib (STI571/Gleevec) are well known inhibitors of BCR-ABL which inhibit the autophosphorylation signal of BCR-ABL in K562 cells with highly reproducible IC50 values. The graph shows representative results.